David Kong
Cardiovascular Disease · Durham, NCNPI 1295819357
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,500 of the $144,359 with a category attached, or 68.9%. Chiesi USA, Inc. accounts for 85.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $78,704 and has fallen 99.4% since, to $481 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $492.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$124K
- Radiometer America, Inc$15K
- Medtronic$3K
- Philips North America LLC$1K
- W. L. Gore & Associates, Inc.$800
- ZOLL Medical Corporation$455
- plus $749 from 3 others
Across 214 payments — averaging $5801.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$710K
- Novo Nordisk AS$370K
- Terumo Medical Corporation$150K
- Abbott$12K
What the payments were for
- Consulting fees$15,42811%
- Speaking & faculty fees$99,50069%
- Travel & lodging$23,84717%
- Food & beverage$5,5844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 249 | $123,746 |
| Radiometer America, Inc | 9 | $14,662 |
| Medtronic(2 entities) | 20 | $2,889 |
| Philips North America LLC | 9 | $1,059 |
| W. L. Gore & Associates, Inc. | 2 | $800 |
| ZOLL Medical Corporation | 1 | $455 |
| BD | 1 | $385 |
| Covidien LP | 1 | $350 |
| Sebela Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KENGREAL$116,349
- HemoCue Plasma/Low Hb Photometer$8,159
- KENGREAL 50MG/10ML L$2,829
- Resolute$1,293
- Product in Development$800
- (BQ9) Coronary IVUS$645
- (6581) Verrata Plus$147
- (6575) Coronary Undivided$102
How this compares
$144,359 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.